The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Oka, Toshitsugu; Hatano, Koji; Okuda, Yoshinobu; Yamamoto, Akinaru; Uemura, Toshihiro; Yamamichi, Gaku; Tomiyama, Eisuke; Ishizuya, Yu; Yamamoto, Yorimasa; Kato, Taigo; Kawashima, Atsunari; Fujita, Kazutoshi; Nonomura, Norio

doi:10.1007/s10147-022-02288-5

Int J Clin Oncol

2022

DOI: 10.1007/s10147-022-02288-5

|View full text |Cite

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Toshitsugu Oka

Koji Hatano

Yoshinobu Okuda

et al.

Abstract: The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer Author(s) Oka, Toshiki; Hatano, Koji; Okuda, Yohei et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Tani,

Hatano,

Yoshimura

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of medication-related osteonecrosis of the jaw (MRONJ). The safety of long-term BMA administration in clinical practice remains unclear. We aimed to determine the cumulative incidence and risk factors of MRONJ. One hundred and seventy-nine patients with prostate cancer with bone metastases treated with BMA at our institution since 2008 were included in this study. Twenty-seven patients (15%) had MRONJ during the follow-up period (median, 19 months; interquartile range, 9–43 months). The 2-year, 5-year, and 10-year cumulative MRONJ incidence rates were 18%, 27%, and 61%, respectively. Multivariate analysis identified denosumab use as a risk factor for MRONJ, compared with zoledronic acid use (HR 4.64, 95% CI 1.93–11.1). Additionally, BMA use at longer than one-month intervals was associated with a lower risk of MRONJ (HR 0.08, 95% CI 0.01–0.64). Furthermore, six or more bone metastases (HR 3.65, 95% CI 1.13–11.7) and diabetes mellitus (HR 5.07, 95% CI 1.68–15.2) were risk factors for stage 2 or more severe MRONJ. MRONJ should be considered during long-term BMA administration in prostate cancer patients with bone metastases.

show abstract

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Tani,

Hatano,

Yoshimura

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Abstract: The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer Author(s) Oka, Toshiki; Hatano, Koji; Okuda, Yohei et al.

Cited by 1 publication

References 32 publications

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Contact Info

Product

Resources

About